Jeremy Lavine Lavine, MD, PhD

I received my MD PhD from the University of Wisconsin-Madison from 2004-2012. During my PhD, I studied how beta-cell mass compensates for obesity to prevent type 2 diabetes mellitus. My background in diabetes research drove me toward ophthalmology and vitreoretinal disease. After my intern year, I resumed my ophthalmology residency training from 2013-2016 at the University of Wisconsin, and completed my surgical vitreoretinal fellowship at the Cleveland Clinic from 2016-2018. During residency, post-doctoral research investigated the role of beta-adrenergic receptor signaling in wet macular degeneration. In September 2018, I began my career as a physician-scientist at Northwestern University, practicing vitreoretinal surgery and investigating macrophage function during macular degeneration. My laboratory currently studies how beta-adrenergic receptor antagonism inhibits wet macular degeneration with an emphasis on macrophages and interleukin-6 signaling. In addition, we are investigating how macrophage origin influences heterogeneity and function at a steady state and during wet macular degeneration. In the collaborative research environment of Northwestern University, with the support of my chairperson and mentors, and with research funding from BrightFocus Foundation, I have the potential to change the paradigm of wet macular degeneration treatment from targeting a single blood vessel growth factor to cell-based therapy.